Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients
Authors:
- 10 February 2022
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 104, 102357
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE studyGenetics in Medicine, 2014
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriersBritish Journal of Cancer, 2014
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- The Influence of BRCA1/BRCA2 Mutations on Toxicity Related to Chemotherapy and Radiotherapy in Early Breast Cancer PatientsOncology, 2013
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 StudyJournal of Clinical Oncology, 2010
- Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of ChemotherapyClinical Cancer Research, 2009
- Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility GeneScience, 2009
- The Prevalence of BRCA2 Mutations in Familial Pancreatic CancerCancer Epidemiology, Biomarkers & Prevention, 2007
- Founder BRCA 1 and 2 Mutations among a Consecutive Series of Ashkenazi Jewish Ovarian Cancer PatientsGynecologic Oncology, 2000